Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06913491

Efficacy of PEEK Acuity Versus ETDRS Chart for Assessment of Visual Acuity and Refractive Error

Visual acuity is a key indicator of visual function, often measured using the ETDRS chart, the gold standard in clinical settings. However, the increasing need for accessible and cost-effective screening tools, especially in underserved areas, has led to the development of mobile health applications like the Peek Acuity application.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Refractive Errors Eye Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Eagle Eyes Relief Trust FF120, Divine mega 2, new airport road

Lahore, Punjab Province, Pakistan

About this study

This study aims to compare the diagnostic accuracy and efficiency of the Peek acuity application (Portable Eye Examination Kit) with the ETDRS (Early Treatment of Diabetic Retinopathy Study) chart in assessing visual acuity and refractive errors. The study will involve 58 participants, selected using a non-probability convenience sampling technique. A comparative cross-sectional design will be used.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males and females.
  • 18 years of age or older.
  • Individuals with normal vision or those with refractive error who had their corrected glasses.
  • Individuals who are willing and able to provide written informed consent to participate in the study.

Exclusion criteria

  • Individuals with anterior segment abnormalities such as conjunctivitis, Iritis, uveitis, keratitis, or corneal ulcers.
  • Individuals with vision deprivation due to corneal opacities, cataracts, glaucoma, retinal, and optic nerve pathologies.
  • Postoperative/intraoperative complications.
  • Have received mydriatic drops.
  • Individuals who cannot achieve normal visual acuity with corrective lenses (glasses or contact lenses).
  • Individuals with neurological conditions affecting vision
  • Individuals unable to cooperate with visual acuity testing due to cognitive impairments or language barriers.
  • Individuals who have had refractive surgery or other eye treatments within the past 6 months.

Treatment and study plan

Primary outcomes

  1. Peek Acuity

    Time frame: 12 Months

    Peek Acuity is easier to administer than an equivalent wall chart, such as Snellen or ETDRS, and is generally quicker to complete. The algorithm that controls progress through each test is optimised for clinical accuracy, so the test will end just as soon as a reliable score has been obtained.

Sponsors and collaborators

Lead sponsor

Superior University

Other

Registry information

Important dates

Study start
2025
Primary completion
2025
Study completion
2026
First posted
Apr 6, 2025
Registry last updated
Apr 6, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.